AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26117150
Drug: Healthcare worker-administered
RxNorm normalized name: Apis cerana worker secretion preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthcare worker-administered LAIV (HCWA)
Trial: 26117150
Drug: Self-administration (SA)
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administration (SA)
Trial: 8522638
Drug: Atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 100 mg orally once daily for 6 days
Trial: 2185026
Drug: Surfactant (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant (100 mg phospholipid/kg, 4 ml/kg)
Trial: 2185026
Drug: Air (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air (4 ml/kg)
Trial: 349091
Drug: Cefamandole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (500 mg every 8 hr for 7 days)
Trial: 349091
Drug: Cefazolin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (500 mg every 8 hr for 7 days)
Trial: 27230855
Drug: 1 mg/d
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/d rasagiline
Trial: 25230559
Drug: Reference group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference group (no antioxidants, drugs, vitamins or dietary supplements)
Trial: 19394598
Drug: Doxycycline 20
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 20 mg orally twice a day after LNG-SI insertion
Trial: 19394598
Drug: Placebo orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally twice a day after LNG-SI insertion
Trial: 22873680
Drug: Granisetron 1
RxNorm normalized name: granisetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 1 mg every 12 hours plus fluvoxamine
Trial: 1627428
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (XRT) with full axillary dissection and gross removal of the tumor, followed by 4500 to 5000 cGy to the whole breast and a boost to the tumor bed of 1500 to 2000 cGy; patients with positive axillary dissections also received cyclophosphamide and doxorubicin
Trial: 30674240
Drug: Valganciclovir 450
RxNorm normalized name: valganciclovir 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir 450 mg daily (group 1)
Trial: 30674240
Drug: Valganciclovir 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir 900 mg daily (group 2)
Trial: 26034151
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg once weekly
Trial: 23016508
Drug: Intramuscular progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular progesterone (250 mg weekly)
Trial: 12036265
Drug: Adaptive two-stage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive two-stage dose-response trial
Trial: 12036265
Drug: Loss-function based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loss-function based approach for dose selection
Trial: 12036265
Drug: Adaptive two-stage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive two-stage designs with dose-selection rule
Trial: 8486515
Drug: Streptomycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptomycin (1 g) with 2% lidocaine (3 ml)
Trial: 8486515
Drug: Lidocaine alone
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine alone (3 ml)
Trial: 2444395
Drug: Topical glucocorticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glucocorticosteroid (flumethasone pivalate 0.02 percent)
Trial: 2444395
Drug: Aqueous solution
RxNorm normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous solution of eosin 2 percent
Trial: 30281180
Drug: Oral chloral
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chloral hydrate at 50 mg kg-1
Trial: 20395941
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) therapy with losartan
Trial: 20395941
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) therapy with atenolol
Trial: 15704099
Drug: EFL group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EFL group (40 teeth treated with fluoride gel and lased)
Trial: 15704099
Drug: EF group
RxNorm normalized name: Klor-Con/EF
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EF group (40 teeth treated with fluoride gel)
Trial: 12590404
Drug: Clomipramine (100-250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (100-250 mg/day)
Trial: 18369175
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and extended-release dipyridamole
Trial: 19924412
Drug: Post-chemotherapy values
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-chemotherapy values
Trial: 2268639
Drug: Conservative stomatological
RxNorm normalized name: STOMATOLOGICAL PREPARATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative stomatological treatment with beta-adrenergic blocking agent 'Obsidan'
Trial: 85006
Drug: Chemotherapy as
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy as the only treatment
Trial: 85006
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus local irradiation
Trial: 85006
Drug: Chemotherapy (Doxorubicin‐containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (Doxorubicin‐containing drug regimens)
Trial: 26606200
Drug: 60-Gy radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60-Gy radiation therapy (RT) with concurrent and consolidation carboplatin/paclitaxel
Trial: 17685720
Drug: Protease supplement
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease supplement
Trial: 15807275
Drug: haiguiyuyang capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: haiguiyuyang capsule
Trial: 8141101
Drug: Ftorafur, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ftorafur, 400 mg/m2/day and Tamoxifen, 20 mg/day (Group B)
Trial: 3051673
Drug: Acetazolamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (250 mg twice a day)
Trial: 28545491
Drug: TESI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TESI plus Levobupivacaine added to oral pain medication
Trial: 28545491
Drug: Transforaminal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal epidural injection (TEI) with Levobupivacaine and saline solution added to oral pain medication
Trial: 28545491
Drug: Oral pain
RxNorm normalized name: Oral Pain Relief
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pain medication
Trial: 19936527
Drug: PA +
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PA + AS (35% phosphoric acid gel + adhesive system)
Trial: 17014560
Drug: Combined low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combined low-dose tacrolimus (2 mg/day) and prednisone (30 mg/day)
Trial: 17014560
Drug: Prednisone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (1 mg/kg per day)
Trial: 28628402
Drug: Calcium supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplement
Trial: 3802729
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet every six hours, beginning two days before lidocaine administration
Trial: 27501015
Drug: Pudendal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pudendal block (0.25% bupivacaine 0.5 mL/kg)
Trial: 27501015
Drug: Caudal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal block (0.2% bupivacaine 1 mL/kg)
Trial: 24316514
Drug: Serelaxin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serelaxin (30 μg/kg/day for 48 hours)
Trial: 19737595
Drug: 37% phosphoric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37% phosphoric acid gel (H(3)PO(4)) for 120s
Trial: 1718477
Drug: Morphine, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine, 1 mg/kg
Trial: 1718477
Drug: Oxymorphone, 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone, 0.2 mg/kg
Trial: 11422884
Drug: Melatonin 6
RxNorm normalized name: melatonin 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 6 mg
Trial: 15677607
Drug: ondansetron (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (16 mg)
Trial: 2904751
Drug: Overall doxazosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall doxazosin therapy
Trial: 2904751
Drug: Doxazosin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin therapy
Trial: 26553313
Drug: Escitalopram 20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 20 mg/day for 52 weeks
Trial: 7534239
Drug: Octreotide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100 micrograms) administered subcutaneously
Trial: 27471804
Drug: 2% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% chlorhexidine gel (CHX), two applications with one-week interval
Trial: 21162925
Drug: No thrombolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No thrombolytic therapy (for Group C)
Trial: 17926468
Drug: Enalapril (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (mean dose 21.9 +/- 9.0 mg/day) with adjuvant indapamide (2.5 mg/day)
Trial: 3522040
Drug: iohexol 240
RxNorm normalized name: iohexol 240 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol 240 mg I/ml
Trial: 2207773
Drug: Higher concentration
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher concentration of iohexol (300 mg I/ml)
Trial: 2207773
Drug: Lower concentration
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower concentration of iohexol (240 mg I/ml)
Trial: 18534496
Drug: High-dose continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose continuous FNB
Trial: 18534496
Drug: Low-dose continuous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose continuous FNB
Trial: 3559150
Drug: PK 8165
RxNorm normalized name: Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PK 8165 (pipequaline) 50 mg
Trial: 24679633
Drug: Rituximab with
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab with bevacizumab (10 mg/kg I.V. on days 3 and 15)
Trial: 24679633
Drug: Rituximab alone
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab alone (375 mg/m(2) I.V. weekly for 4 weeks)
Trial: 16192516
Drug: PPI (rabeprazol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI (rabeprazol 20 mg)
Trial: 16192516
Drug: H2 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 group (roxatidine 75 mg)
Trial: 12523578
Drug: Oral valacyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valacyclovir (VAL), 1 g orally every 12 hours from day 0 to engraftment
Trial: 12523578
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir (ACY), 250 mg/m2 intravenously every 12 hours from day 0 to engraftment
Trial: 6262206
Drug: FK 33-824,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK 33-824, 0.5 mg i.m.
Trial: 15605688
Drug: Cefuroxime axetil/Pharmathen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil/Pharmathen (test preparation)
Trial: 13937554
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 16% antivaccinia gamma-globulin (AGG)
Trial: 10867377
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy
Trial: 31487117
Drug: Topical Cadexomer
RxNorm normalized name: cadexomer iodine Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Cadexomer Iodine for 2 weeks
Trial: 31487117
Drug: Topical Cadexomer
RxNorm normalized name: cadexomer iodine Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Cadexomer Iodine for 6 weeks
Trial: 31487117
Drug: Topical Cadexomer
RxNorm normalized name: cadexomer iodine Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Cadexomer Iodine (both durations)
Trial: 26123832
Drug: Multimodal maternal
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimodal maternal ADHD treatment (group psychotherapy plus open methylphenidate medication; treatment group (TG): n = 77)
Trial: 19185670
Drug: 24/4 regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24/4 regimen of 20 mcg ethinyl estradiol and 1 mg norethindrone acetate
Trial: 19185670
Drug: 21/7 regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21/7 regimen of 20 mcg ethinyl estradiol and 1 mg norethindrone acetate
Trial: 9159562
Drug: imidapril 10
RxNorm normalized name: imidapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imidapril 10 mg day(‐1) + digoxin 0.25 mg day(‐1) (I + D)
Trial: 9159562
Drug: imidapril 10
RxNorm normalized name: imidapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imidapril 10 mg day(‐1) + placebo (I + P)
Trial: 20306354
Drug: Narrative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative therapy (8 sessions)
Trial: 17947224
Drug: Sequential TAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential TAM
Trial: 8836986
Drug: L-DOPA +
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-DOPA + L-threo-DOPS
Trial: 8836986
Drug: L-threo-DOPS
RxNorm normalized name: L-DOPS
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-threo-DOPS
Trial: 6439648
Drug: Beta-carotene (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (180 mg/week in 6 capsules)
Trial: 6439648
Drug: Canthaxanthin (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canthaxanthin (180 mg/week in 6 capsules)
Trial: 24707145
Drug: 10-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-day regimen of amoxicillin 1 g, clarithromycin 500 mg, and rabeprazole 20 mg twice daily
Trial: 2899496
Drug: Cefotaxime and
RxNorm normalized name: cefotaxime and beta-lactamase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime and metronidazole (75 mg/kg and 10 mg/kg intravenously in 3 doses at 12-hourly intervals) plus peritoneal lavage with cefotaxime 2 g/L during surgery (group 2)
Trial: 25466655
Drug: Glutamine 30
RxNorm normalized name: glutamine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine 30 g/d (10 g powder, three times a day)
Trial: 18060377
Drug: Compliance-enhancing program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compliance-enhancing program in patients with statin therapy
Trial: 10738435
Drug: Antibiotic beads
RxNorm normalized name: Bead Tree Leaf
DrugBank: Azadirachta indica leaf (DB14352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic beads
Trial: 10738435
Drug: Conventional intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intravenous antibiotics
Trial: 10738435
Drug: Antibiotic beads
RxNorm normalized name: Bead Tree Leaf
DrugBank: Azadirachta indica leaf (DB14352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic beads and intravenous antibiotics (nonrandomized third cohort)
Trial: 2987294
Drug: Prednisone (glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (glucocorticoid therapy)
Trial: 30217229
Drug: Probiotic and
RxNorm normalized name: Florastor Advanced Probiotic And Digestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic and selenium co-supplementation (8×10^9 CFU/day probiotic plus 200 μg/day selenium)
Trial: 14665500
Drug: Modafinil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (200 to 400 mg qd)
Trial: 11009043
Drug: Formoterol (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (9 microg twice daily)
Trial: 10451943
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (steroid, cyclophosphamide, and bennazipril)
Trial: 10451943
Drug: LMWH (fraxiparin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH (fraxiparin) 60 anti Xa IU.kg‐1.day‐1 plus steroid, cyclophosphamide, and bennazipril
Trial: 1589566
Drug: Zolpidem (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (20 mg)
Trial: 2667400
Drug: Triazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.5 mg)
Trial: 29417761
Drug: M923 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M923 (40 mg)
Trial: 27468258
Drug: BCAAs and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAAs and CHO (3 g/d L-leucine, 1 g/d L-isoleucine, 2 g/d L-valine with 2 g of CHO; n=15)
Trial: 27468258
Drug: CHO only
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO only (42 g of CHO; n=15)
Trial: 20645530
Drug: Ustekinumab 22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 22.5 or 45 mg/kg s.c. (n = 32)
Trial: 20645530
Drug: Ustekinumab 0.09-4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 0.09-4.5 mg/kg i.v. or 0.27-2.7 mg/kg s.c. (n = 46)
Trial: 16288390
Drug: Moxifloxacin (MXF)
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (MXF) 400 mg once daily intravenously, possibly followed by oral tablets
Trial: 16288390
Drug: Ceftriaxone (CTRX)
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (CTRX) 2 g intravenously once daily with or without Erythromycin (ERY) 1 g intravenously every 6-8 h
Trial: 2929629
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg caffeine
Trial: 26096318
Drug: Task-Based Mirror
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-Based Mirror Therapy (TBMT)
Trial: 19737441
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg mecamylamine
Trial: 17691588
Drug: Iron(III)-hydroxide polymaltose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron(III)-hydroxide polymaltose complex (IPC, Maltofer) with tetracycline (2 x 250 mg capsules)
Trial: 17691588
Drug: Tetracycline alone
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline alone (2 x 250 mg capsules)
Trial: 12576956
Drug: Intravenous nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nicorandil (6 mg/hr continuous infusion for 60 mins)
Trial: 12576956
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (normal saline, 6 mL/hr continuous infusion)
Trial: 31013851
Drug: Low-dose CW
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CW (300 mg/d)
Trial: 31013851
Drug: High-dose CW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CW (600 mg/d)
Trial: 20825373
Drug: Weekly severity
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly severity ratings of manic symptoms
Trial: 19325997
Drug: 0.25 microg
RxNorm normalized name: calcitriol 0.25 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 microg oral alphacalcidol twice daily for 6 months
Trial: 20181806
Drug: Fish oils
RxNorm normalized name: fish oils
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oils (4 g/d)
Trial: 18566295
Drug: Atorvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40 mg/d)
Trial: 16825679
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Fish oils and Atorvastatin